NCT06894407View on ClinicalTrials.gov

Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Cutaneous Metastatic Melanoma
Interventions
DEVICE

Device: Targeted Hyperthermia Therapy

Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy.

All Listed Sponsors
lead

Sona Nanotech Inc

INDUSTRY

NCT06894407 - Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma | Biotech Hunter | Biotech Hunter